Big pharma scores first victory in IPR battle with Bass and Spangenberg, but the war is far from over
As anyone keeping score will know it’s currently big pharma 2 – Kyle Bass/Erich Spangenberg 0. The decision earlier this week by the Patent Trial and Appeal Board (PTAB) not to institute inter partes reviews of two patents owned by pharmaceutical…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.
Subscribe now